MediumEndocrinologyType 2 diabetes with cardiovascular diseaseca-mccqe1ca-rcpsc-im
A 60-year-old man with type 2 diabetes, obesity and established coronary artery disease is on metformin and lifestyle measures. His HbA1c is 7.6%. eGFR is 65 mL/min/1.73 m² and he has no history of ketoacidosis. According to updated Diabetes Canada guidance, which additional agent is preferred to reduce cardiovascular risk?